January 24, 2017 -- Aslan Pharma of Singapore was approved to list on Taiwan’s Taipei Stock Exchange, Taiwan’s main board. Before being admitted to TPEX, a company must first be listed for six months on Taiwan’s OTC market, sometimes known as the GreTai exchange. Aslan has met that requirement, and it will, presumably, at some point conduct a public fundraising event, though the company has not yet disclosed its plans. Founded in 2010, Aslan raised $23 million in pre-IPO venture capital last July, bringing its total VC funding to more than $100 million.
